BioinvestGPT ApS · Research use only
BVCT solutions
19 case studies and newsletters from BioinvestGPT, each featuring a unique BVCT capability, from Reuters-reported virtual trials of high-profile readouts, atom-level clinical benefit prediction, patient-data-free calls made before the first patient enrols, first-in-class mechanism calls that look past the biomarker, any-phase calls spanning Phase 1/2 and Phase 3, pipeline-level GO/NO-GO calls, portfolio-wide NO-GO calls shared before the readouts, clinical benefit prediction from mRNA sequence, Phase 3 outcome calls made well before the readout, PFS/OS discordance calls, overall-survival calls in HER2-positive cancers, sealed calls on the year’s most-watched readouts, variant-level clinical derisking before wet-lab spend, verification of AI co-scientist hypotheses, in vivo CAR-T design simulation, ADC design and biomarker discovery, clinical prediction from the genome alone, mathematics-based hazard-ratio prediction, to a self-service GO/NO-GO web app. Each cited prediction links to its trial page, with the prediction date, the recorded calls and the readout classification.
In the news
- In the news · Reuters · 7 Oct 2026Reuters reports five of six BVCT trial calls right; four NO-GO calls remain openReuters reported that five of six BVCT calls on closely watched trials were right. See the four dashboard records, the pelacarsen miss and four open calls.4 dashboard predictions cited
Pipeline and asset case studies
- Case study · ZiltivekimabZiltivekimab: ZEUS, HERMES, ATHENA. Three BVCT NO-GOs, already on record.BVCT locked NO-GO calls on ziltivekimab for ZEUS, HERMES and ATHENA on 24 Mar 2024. ZEUS missed its primary endpoint on 31 Jul 2026.5 dashboard predictions cited
- Case study · ATHENA · ZiltivekimabBefore the first patient was enrolled, BVCT called NO-GO on ATHENA — from Drug MoA and the protocol alone.BVCT locked its NO-GO on ATHENA (ziltivekimab) on 24 Mar 2024, 8 days before the first participant was enrolled, from the mechanism and public protocol.1 dashboard prediction cited
- Case study · AOC 1001 (del-desiran) in DM1 · 23 Sep 2026HARBOR missed on 8 September 2026. The NO-GO was sealed 1,235 days earlier.BVCT sealed a FAILURE call on AOC 1001 on 22 Apr 2023, at Phase 1/2, and again at Phase 3; HARBOR missed its primary endpoint on 8 Sep 2026.2 dashboard predictions cited
- Case study · Sanofi pipeline · 30 Jul 2026Sanofi’s 10+ post-readout decisions mirror BVCT’s pre-readout calls sent to Sanofi well in advanceThirteen BVCT calls on Sanofi trials, sealed 18 Apr 2025 and sent to Sanofi: eleven adjudicable, all classified TP or TN; one pending, one not adjudicable.12 dashboard predictions cited
- Case study · Aficamten vs mavacamten in non-obstructive HCM · 14 May 2026Two Verdicts. Same Indication. Both Right.From molecular differences, BVCT called mavacamten (No. 1959) 12 days and aficamten (No. 2094) months before their non-obstructive HCM readouts.4 dashboard predictions cited
- Case study · Novo Nordisk pipeline · 18 Aug 2026Ziltivekimab. CagriSema. Monlunabant. BVCT Shared those NO-GOs with Novo Leadership Before the Readouts.BVCT sealed NO-GO calls on ziltivekimab, CagriSema and monlunabant in 2024 and sent them to Novo Nordisk R&D before each readout. All three: TN.5 dashboard predictions cited
- Case study · Moderna pipeline · 28 Aug 2026BVCT predicted clinical benefit from mRNA sequence in 7 days with 4-for-4 ex-ante GO/NO-GO accuracy on Moderna readouts.BVCT called four Moderna mRNA readouts ex ante: GO on intismeran autogene, NO-GO on mRNA-1010, mRNA-1647 and VX-522. All four classified TP or TN.4 dashboard predictions cited
- Case study · Eplontersen in ATTR-CM · 12 Aug 2026AstraZeneca Could Have Avoided a £19 Billion Loss with BVCT.BVCT sealed its eplontersen ATTR-CM call on 12 Dec 2024, 574 days before CARDIO-TTRansform missed its primary endpoint on 9 Jul 2026.1 dashboard prediction cited
- Case study · Tovecimig · PFS/OS discordance · 4 May 2026Patient-Data-Free BVCTs Eliminate PFS-OS Discordance Before DecisionsBVCT called PFS superior and DLL4-dependent OS for tovecimig in COMPANION-002 (No. 1195) on 3 Nov 2024. The 27 Apr 2026 readout: PFS superior, OS not.11 dashboard predictions cited
- Case study · ZanidatamabWe called the Zanidatamab triplet’s OS benefit, locked 19 Jan 2025, 302 days before the readoutBVCT locked its call on the zanidatamab triplet in HERIZON-GEA-01 (No. 590) on 19 Jan 2025, 302 days before the readout, after three earlier HER2+ calls.4 dashboard predictions cited
Calls ahead of readouts
- Calls ahead of readouts · BioPharma Dive’s 2H 2026 watch list · 28 Jul 2026All Ten Most-Anticipated Readouts of 2H 2026. Called Before the Data.Fourteen sealed BVCT calls on the ten entries BioPharma Dive listed for 2H 2026: seven GO, seven NO-GO. Three are scored on the dashboard so far.3 dashboard predictions cited
Platform and perspective
- Platform · Genetic variants · 8 Jul 2026Clinically Derisk Every Genetic Variant Before Preclinical Spend.BVCT simulates a Phase-III effect size vs standard of care for each candidate variant, patient-data-free. VERVE-101 was called FAILURE 12 days before data.3 dashboard predictions cited
- Platform · BVCT and pharma AI co-scientists · 2 Jun 2026The Clinical Derisking Layer for Every Pharma AI Co-Scientist.How BVCT scores AI co-scientist hypotheses by simulated Phase III effect size vs standard of care, with mavacamten (No. 1959) and aficamten (No. 2094).2 dashboard predictions cited
- Decisive clinical advantage · In vivo CAR-T design · 23 Apr 2026The Clinical GPS of in vivo CAR-T DesignBVCT simulates in vivo CAR-T design features, from fusogens to payload decay, to forecast effect size (HR, ORR) against a competitor in vivo CAR-T or SoC.
- Decisive clinical advantage · ADC designThe Clinical GPS of BeatSoC ADC Drug Design and Biomarker DiscoveryBVCT simulates how each ADC design and patient stratification parameter changes the PFS/OS hazard ratio vs standard of care, without retrospective RWD.
- Patient-Data-Free · TRL-9 · Deployed · 3 May 2026The Genome Is Enough — A TRL-9 Existence ProofBVCT predicts the clinical-benefit hazard ratio of any candidate drug versus standard of care from the genome, with no patient data ingested.
- Perspective · Mathematics, not data · 4 May 2026Mathematics is EnoughWhy BVCT predicts Phase-3 hazard ratios from mathematics and the genome, with no patient data, where statistical AI is structurally blind.
- BioinvestGPT · BVCT web app · Introduction · 22 Apr 2026Gain clinical foresight before every decision.The BVCT web app: predicted clinical effect sizes vs standard of care, a causal knowledge graph and virtual clinical trials for every GO/NO-GO decision.